34 results on '"Edelman, Martin J."'
Search Results
2. Appropriate Use Criteria (AUC) for the Management of Non-Small Cell Lung Cancer in a Central/Ultra-Central Location: Guidelines from the American Radium Society
3. SWOG S1400C (NCT02154490)—A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration–Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)
4. American Radium Society Appropriate Use Criteria: Radiation Therapy for Limited-Stage SCLC 2020
5. American Radium Society Appropriate Use Criteria on Radiation Therapy for Extensive-Stage SCLC
6. Alternative Multidisciplinary Management Options for Locally Advanced NSCLC During the Coronavirus Disease 2019 Global Pandemic
7. Time-to-Treatment-Failure and Related Outcomes Among 1000+ Advanced Non–Small Cell Lung Cancer Patients: Comparisons Between Older Versus Younger Patients (Alliance A151711)
8. Randomized Phase II Study of Preoperative Chemoradiotherapy ± Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Non–Small Cell Lung Cancer: NRG Oncology RTOG 0839
9. Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study—CALGB 30607 (Alliance)
10. Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?
11. Impact of an Interactive On-line Tool on Therapeutic Decision-Making for Patients with Advanced Non-Small-Cell Lung Cancer
12. Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View
13. CYFRA 21-1 as a Prognostic and Predictive Marker in Advanced Non–Small-Cell Lung Cancer in a Prospective Trial: CALGB 150304
14. Serum Vascular Endothelial Growth Factor and COX-2/5-LOX Inhibition in Advanced Non-small Cell Lung Cancer: Cancer and Leukemia Group B 150304
15. Bortezomib for Patients with Advanced-Stage Bronchioloalveolar Carcinoma: A California Cancer Consortium Phase II Study (NCI 7003)
16. Population-Based Estimates of Survival Benefit Associated with Combined Modality Therapy in Elderly Patients with Locally Advanced Non-small Cell Lung Cancer
17. Multicenter Phase II Trial of Motexafin Gadolinium and Pemetrexed for Second-Line Treatment in Patients with Non-small Cell Lung Cancer
18. Outcomes Associated with Brain Metastases in a Three-Arm Phase III Trial of Gemcitabine-Containing Regimens Versus Paclitaxel Plus Carboplatin for Advanced Non-small Cell Lung Cancer
19. Targeted Radiopharmaceutical Therapy for Advanced Lung Cancer: Phase I Trial of Rhenium Re188 P2045, a Somatostatin Analog
20. Pemetrexed plus Cetuximab in Patients with Recurrent Non-small Cell Lung Cancer (NSCLC): A Phase I/II Study from the Hoosier Oncology Group
21. Phase 1-2a Multicenter Dose-Ranging Study of Canfosfamide in Combination with Carboplatin and Paclitaxel as First-Line Therapy for Patients with Advanced Non-small Cell Lung Cancer
22. Phase II Randomized Study of Dose-Dense Docetaxel and Cisplatin Every 2 Weeks With Pegfilgrastim and Darbepoetin Alfa With and Without the Chemoprotector BNP7787 in Patients With Advanced Non-small Cell Lung Cancer (CALGB 30303)
23. Neoadjuvant Chemotherapy with Gemcitabine-Containing Regimens in Patients with Early-Stage Non-small Cell Lung Cancer
24. Obatoclax Mesylate, a Pan–Bcl-2 Inhibitor, in Combination with Docetaxel in a Phase 1/2 Trial in Relapsed Non–Small-Cell Lung Cancer
25. Lung Cancer in HIV-Infected Patients in the Era of Highly Active Antiretroviral Therapy
26. Novel Cytotoxic Agents for Non-small Cell Lung Cancer
27. Multicenter Trial of EC145 in Advanced, Folate-Receptor Positive Adenocarcinoma of the Lung
28. EML4/ALK and Ras Inhibitors
29. Pemetrexed-Induced Typhlitis in Non-small Cell Lung Cancer
30. Appropriate Use Criteria (AUC) for Non-Small Cell Lung Cancer in a Central/Ultra-Central Location: Executive Summary of the American Radium Society's Systematic Review and Guidelines
31. M08-03: Is there a role for COX-2 inhibition in lung cancer?
32. P2-174: ERCC1 and Beta Tubulin III (BTUB) isoform expression by Immunofluorescence (IF) may correlate with survival after combined modality therapy (CMT) for stage III NSCLC
33. ERCC1 and Beta Tubulin III (BTUB) isoform expression by Immunofluorescence (IF) may correlate with survival after combined modality therapy (CMT) for stage III NSCLC.
34. Is there a role for COX-2 inhibition in lung cancer?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.